13 Feb 2024 • Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and a unique binding site, providing well balanced inhibition of two type II topoisomerase enzymes, is currently under investigation to treat uncomplicated urinary tract infections.

• Gepotidacin has proven its non-inferiority to nitrofurantoin and efficacy against uncomplicated UTIs.
• Gepotidacin's showcased its potential against drug-resistant uropathogens in 2 key phase 3 trials i.e EAGLE-2 and EAGLE-3 studies.
• Notably, the primary analysis showed therapeutic success in 50.6% of gepotidacin-treated patients in EAGLE-2 and 58.5% in EAGLE-3.
• Safety analyses reported manageable adverse events, with diarrhea being the most common for gepotidacin.

Source: The Lancet | Read full story